CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Insulin (Humulin) 40 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00646581
NCT00646581Phase 4Completed

Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia

University of Massachusetts, Worcester·interventional·Posted Mar 28, 2008·Updated Feb 15, 2013

In Brief

A Phase 4 clinical trial evaluating Placebo and Insulin (Humulin) for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include: 1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 28, 2008
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.3 years ago

Interventions

Placebodrug

Placebo

Insulin (Humulin)drug

40 IU Intranasal Insulin will be administered once